Affimed Reports Financial Results for Third Quarter 2016
Heidelberg, Germany, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Heidelberg, Germany, November 2, 2016 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, today …